NSE: TATVA | BSE: 543321

Expensive Performer

Download real time

1060.10 -8.20 (-0.77%)

70.71% Gain from 52W Low

13,500 NSE+BSE Volume

NSE 14 Aug, 2025 10:38 AM (IST)

2,479.8

Market Cap

Below industry Median

0.6

Beta 1Year

Very Low volatility

Tatva Chintan Pharma Chem Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for TATVA, BSE:543321 Tatva Chintan Pharma Chem Ltd.

Search Inside the pdf :

Tatva Chintan Pharma Chem Ltd.

06 May 2025

1060.10

-0.77%

TATVA remain hopeful for strong recovery in FY26

Buy: Tatva Chintan Pharma Chem ...

Target

ICICI Securities Limited

Tatva Chintan Pharma Chem’s (TATVA) performance showed signs of improvement in Q4FY25 on the revenue front, but lower gross profit marred profit recovery. TATVA is hopeful of a sharp recovery in FY26, as new products commercialise in PASC and SDA volume recovers.

Tatva Chintan Pharma Chem Ltd. has gained 42.57% in the last 6 Months

Tatva Chintan Pharma Chem Ltd.

25 Jul 2024

1060.10

-0.77%

Margins impacted by high-cost inventory

Buy: Tatva Chintan Pharma Chem ...

Target

ICICI Securities Limited

Tatva Chintan Pharma Chem’s (TATVA) revenue grew 7.3% QoQ, but gross profit margin collapsed to just 45.9% (vs 57.8% in Q4FY24) due to high-cost inventory, particularly in SDA, where it had to take 15-20% price.

Tatva Chintan Pharma Chem Ltd. has gained 38.71% in the last 3 Months

Tatva Chintan Pharma Chem Ltd.

27 Sep 2023

1060.10

-0.77%

Core business normalising; new products pipeline maturing

Buy: Tatva Chintan Pharma Chem ...

Target

ICICI Securities Limited

In FY23, Tatva Chintan (TATVA) earnings were hurt from a downcycle in its SDA business, which should resume growing FY24 onwards. The addition of a significant new customer to its SDA has the potential to propel growth in the near future. PASC segment will likely reap the benefit of products under qualification and long-term growth on the back of a robust pipeline and cleaner chemistry positioning.

Tatva Chintan Pharma Chem Ltd. is trading above all available SMAs

Tatva Chintan Pharma Chem Ltd.

06 May 2023

1060.10

-0.77%

Near-term weakness weighs on FY25 guidance

Buy: Tatva Chintan Pharma Chem ...

Target

ICICI Securities Limited

Tatva Chintan’s Q4FY23 revenue rose 26.4% YoY to Rs1.2bn as SDA revenue recovered to Rs0.5bn, up 41% YoY. However, gross profit margin dip of 400bps to 39.8% was disappointing (partly from a change in product mix) considering the company has guided for a sequential improvement in margins.

Tatva Chintan Pharma Chem Ltd. has gained 42.57% in the last 6 Months

Tatva Chintan Pharma Chem Ltd.

25 Jan 2023

1060.10

-0.77%

SDA revenue recovers; but margins dip

Buy: Tatva Chintan Pharma Chem ...

Target

ICICI Securities Limited

Tatva Chintan’s Q3FY23 revenue rose 15% YoY / 34% QoQ to Rs1.2bn as SDA revenue recovered to Rs0.6bn, up 6.4% YoY / 5.7x QoQ. However, non-SDA segments, which hitherto performed well, dipped QoQ. The disappointment come from an 800bps QoQ contraction in gross profit margin to 43.8% due to higher bromine and solvent prices, which have subsequently corrected.

Tatva Chintan Pharma Chem Ltd. has gained 42.57% in the last 6 Months

Tatva Chintan Pharma Chem Ltd.

07 Nov 2022

1060.10

-0.77%

Rising visibility on FY24E EPS growth

Buy: Tatva Chintan Pharma Chem ...

Target

ICICI Securities Limited

Tatva Chintan’s Q2FY23 revenue fell 27.1% YoY and EBITDA plunged 68.9% YoY due
to lower SDA sales, which seems very disappointing, but we believe this situation is
transitory.

Tatva Chintan Pharma.. has an average target of 1000.00 from 1 broker.

Tatva Chintan Pharma Chem Ltd.

26 Apr 2022

1060.10

-0.77%

Strong pipeline of high-value new products

Buy: Tatva Chintan Pharma Chem ...

Target

ICICI Securities Limited

Tatva Chintan’s Q4FY22 revenue declined 9.3% YoY and was 11% below our estimates on higher dip in SDA revenue. However, gross margin expansion of 280bps QoQ, despite inferior revenue mix, was a positive surprise. It anticipates SDA revival only in H2FY23, and has guided for flattish revenue for FY23. However, we expect an upside risk if auto production normalises, and benefits from pent-up demand and large inventory get liquidated.

Tatva Chintan Pharma Chem Ltd. has gained 38.71% in the last 3 Months

Tatva Chintan Pharma Chem Ltd.

19 Dec 2021

1060.10

-0.77%

‘Smart and green’ chemistry – our preferred play

Buy: Tatva Chintan Pharma Chem ...

ICICI Securities Limited

We initiate coverage on Tatva Chintan Pharma Chem (Tatva Chintan) with a BUY rating, and Clean Science & Technology (Clean Science) with a REDUCE rating. These two companies operate in niche categories with significant exposure to smart and green chemistries.

Tatva Chintan Pharma Chem Ltd. is trading above all available SMAs

Tatva Chintan Pharma Chem Ltd.

15 Jul 2021

1060.10

-0.77%

Tatva Chintan Pharma Chem Limited IPO Note

IPO Note: Tatva Chintan Pharma Chem ...

HDFC Securities

Tatva Chintan Pharma Chem Limited IPO Note Issue Open: July 16 July 20 2021 Price Band: Rs. 1073 1083 *Issue Size: 4,616,805 eq shares (Fresh Issue of 225 cr + Offer for sale of 275 cr) Issue Size: Rs.500.0 cr Reservation for: QIB Upto 50% eq sh Non Institutional atleast 15% eq sh Retail Upto 35% eq sh

Tatva Chintan Pharma Chem Ltd. is trading above all available SMAs

Tatva Chintan Pharma Chem Ltd.

15 Jul 2021

1060.10

-0.77%

TATVA CHINTAN LIMITED

IPO Subscribe: Tatva Chintan Pharma Chem ...

Angel Broking

Incorporated in 1996, Tatva Chintan Pharma Chem Limited (Tatva Chintan) is a leading manufacturer of Structure Directing Agents (SDAs) and Phase Transfer Catalyst (PTCs) that have various applications in green chemistry. The company also manufactures Electrolyte Salts for super capacitor batteries (SCB) and Pharmaceutical & Agrochemical intermediates and other specialty chemicals (PASC). Its Product have

Tatva Chintan Pharma.. has an average target of 1000.00 from 1 broker.

VOTE: Is Tatva Chintan Pharma Chem Ltd. worth buying?

51 Votes:

Buy 56.86%

Sell 23.53%

Hold 19.61%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf